Skip to main content
. 2019 Jul 27;11(2):490–498. doi: 10.1111/jdi.13112

Table 2.

Characteristics of women with breast cancer stratified by receiving hormone therapy

Variable Hormone therapy No hormone therapy P‐value
n = 2,812 n = 1,795
Age group
Mean (SD) 59.0 (9.2) 57.8 (8.8) <0.001
55–65 years 2,216 (78.8) 1,498 (83.4) <0.001
66–80 years 522 (18.6) 260 (14.5)  
≥81 years 74 (2.6) 37 (2.1)  
Income
<1,249 826 (29.4) 565 (31.5) 0.299
1,249–21,899 853 (30.3) 536 (29.9)  
≥21,900 1,133 (40.3) 694 (38.7)  
Urbanization
I (1) 994 (35.4) 634 (35.3) 0.877
II (2 + 3) 1,046 (37.2) 678 (37.8)  
III (4 + 5) 336 (12.0) 221 (12.3)  
IV (6 + 7) 133 (4.7) 74 (4.1)  
Missing 303 (10.8) 188 (10.5)  
Cancer stage
1 767 (35.3) 356 (32.5) 0.087
2 896 (41.3) 448 (41.0)  
3 392 (18.1) 236 (21.6)  
4 116 (5.3) 54 (4.9)  
Charlson Comorbidity Index
Mean (SD) 0.7 (1.6) 0.5 (1.2) <0.001
>1 446 (15.9) 246 (13.7) 0.046
History of hyperlipidemia 316 (11.2) 161 (9.0) 0.014
History of hypertension 773 (27.5) 404 (22.5) <0.001
History of cardiovascular disease 186 (6.6) 115 (6.4) 0.781
History of chronic kidney disease 15 (0.5) 10 (0.6) 0.915
History of cerebrovascular disease 100 (3.6) 55 (3.1) 0.366
Received treatment within 1 year after index date
Surgery 2,710 (96.4) 1,293 (72.0) <0.001
Chemotherapy 1,732 (61.6) 848 (47.2) <0.001
Median follow‐up period, years (IQR) 3.1 (0.1–6.8) 4.1 (1.0–8.5) <0.001

Data are presented as mean ± standard deviation (SD), number (percentage) or median (interquartile range [IQR]). Patients were divided into four subgroups according to the level of urbanization where they resided: I (1): highly urbanized cities; II (2 + 3): moderately urbanized cities plus boom towns; III (4 + 5): general cities and towns plus aging towns; IV (6 + 7): suburbanized cities and towns plus remote towns.